LB-100

Generic Name
LB-100
Brand Names
-
Drug Type
Small Molecule
Chemical Formula
C13H20N2O4
CAS Number
1632032-53-1
Unique Ingredient Identifier
0C1JUU9S0L
Background

LB-100 is under investigation in clinical trial NCT03886662 (A Study of LB-100 in Patients With Low or Intermediate-1 Risk Myelodysplastic Syndromes (MDS)).

Associated Conditions
-
Associated Therapies
-
Clinical Trials
Related News

Safety and Efficacy of Targeting PP2A in Ovarian Clear Cell Carcinoma Using Dostarlimab and LB-100

Phase 1
Recruiting
Conditions
Ovarian Clear Cell Carcinoma
Interventions
Drug: Dostarlimab
Drug: LB-100
First Posted Date
2023-10-04
Last Posted Date
2024-08-28
Lead Sponsor
M.D. Anderson Cancer Center
Target Recruit Count
21
Registration Number
NCT06065462
Locations
🇺🇸

M D Anderson Cancer Center, Houston, Texas, United States

LB-100 (PP2A Inhibitor) and Atezolizumab (PD-L1 Inhibitor) in Metastatic Colorectal Cancer Patients

First Posted Date
2023-08-25
Last Posted Date
2023-09-05
Lead Sponsor
The Netherlands Cancer Institute
Target Recruit Count
37
Registration Number
NCT06012734
Locations
🇳🇱

Antoni van Leeuwenhoek, Amsterdam, Noord Holland, Netherlands

A Study of LB-100 in Patients With Low or Intermediate-1 Risk Myelodysplastic Syndromes (MDS)

Phase 1
Recruiting
Conditions
Myelodysplastic Syndromes
Interventions
Drug: LB-100
First Posted Date
2019-03-22
Last Posted Date
2019-04-08
Lead Sponsor
Lixte Biotechnology Holdings, Inc.
Target Recruit Count
47
Registration Number
NCT03886662
Locations
🇺🇸

H. Lee Moffitt Cancer Center & Research Institute, Tampa, Florida, United States

Protein Phosphatase 2A Inhibitor, in Recurrent Glioblastoma

First Posted Date
2017-01-23
Last Posted Date
2023-11-22
Lead Sponsor
National Cancer Institute (NCI)
Target Recruit Count
7
Registration Number
NCT03027388
Locations
🇺🇸

National Institutes of Health Clinical Center, Bethesda, Maryland, United States

© Copyright 2024. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy